trafficking protein particle complex subunit 3LGenealiases: BET3L · bA259P20.2
Q-omics provides the consensus-scored TRAPPC3L profile across patient tissues and cancer cell-line models. TRAPPC3L expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRAPPC3L is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, TRAPPC3L RNA expression shows 15,146 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KICH, and TGCT as cancer lineages where TRAPPC3L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAPPC3L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAPPC3L survival associations across molecular data types. TRAPPC3L RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAPPC3L RNA expression–survival associations across cancer types. High TRAPPC3L expression shows unfavorable associations in BLCA and UVM, but favorable associations in SKCM, KIRC, COAD and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRAPPC3L RNA expression.
This table summarizes TRAPPC3L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TRAPPC3L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAPPC3L shows lower tumor expression in KICH, KIRP, LUAD, LIHC, COAD and LUSC. The KICH box plot shows higher TRAPPC3L RNA expression in normal versus tumor tissue (log2 FC = −0.413, t-test p < 0.001).
This table shows molecular features associated with TRAPPC3L in patient tissues and cancer cell lines. In patient samples, TRAPPC3L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TRAPPC3L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
